pSivida Corp



We have three FDA-approved products, Vitrasert and Retisert®, both licensed to Bausch and Lomb, and Iluvien licensed to Alimera Sciences.

Our most recently approved product, ILUVIEN® (partnered with Alimera Sciences) for the treatment of vision impairment associated with chronic DME insufficiently responsive to available therapies, has received marketing authorization in the UK, Austria, France, Germany, Portugal, Spain, Italy, Norway, Denmark, the Netherlands, Belguim, Ireland and Sweden.

Our next furthest advanced product is Durasert™ for posterior uveitis, which we are developing independently. This product is the same drug delivery devise used in ILUVIEN for DME. The FDA is permitting us to reference all of the data used by Alimera in its regulatory submissions of ILUVIEN in DME (including clinical, nonclinical, manufacturing and stability data) in any potential posterior uveitis regulatory filings.

Our bioerodible glaucoma product, being developed under our collaboration with Pfizer, is currently in Phase I/II clinical trials.

Pre-clinical programs include Tethadur™, our BioSilicon-based protein delivery system designed to provide sustained release of antibodies, and a bioerodible neuroprotective agent.

Click here for more information on partnering with pSivida. »